Castle Biosciences, Inc. Chief Commercial Officer Tobin Juvenal filed a Form 144 notice on November 9, 2026, disclosing a proposed sale of 13,154 shares of common stock through Goldman Sachs & Co. LLC with an aggregate market value of $452,234.52.
Key Highlights
- Proposed sale: Tobin Juvenal, Chief Commercial Officer of Castle Biosciences, Inc., intends to sell 13,154 shares of common stock.
- Aggregate market value: The proposed shares carry an aggregate market value of $452,234.52, according to the filing.
- Shares outstanding: The filing lists 30,818,291 shares of common stock outstanding.
- Acquisition sources: The shares to be sold were acquired as compensation through Restricted Stock Units, Restricted Stock Awards, and Performance Awards from the issuer, with acquisition dates ranging from February 28, 2020 to August 8, 2025.
- 10b5-1 plan: The filing states the sales "are made in connection with a selling plan dated 5/28/2026 that is intended to comply with Rule 10b5-1(c)."
- Approximate date of sale: The proposed sale date is listed as November 9, 2026, through the NASD exchange.
- Recent sales: The filing discloses 15 prior transactions by Juvenal in the past three months, totaling shares sold across dates from August 17, 2026 through October 28, 2026.
Castle Biosciences CCO Discloses Proposed November 2026 Share Sale Under 10b5-1 Plan
According to the Form 144 notice filed on November 9, 2026, Tobin Juvenal, the Chief Commercial Officer of Castle Biosciences, Inc. (issuer SEC File Number 001-38984), proposes to sell 13,154 shares of common stock. The broker named in the filing is Goldman Sachs & Co. LLC, located at 200 West Street, New York, NY 10282. The aggregate market value of the proposed sale is listed as $452,234.52, with 30,818,291 total shares of common stock outstanding at the time of filing.
The filing identifies seven separate acquisition tranches underlying the shares to be sold. These include Restricted Stock Units acquired on December 10, 2023 (1,012 shares) and December 9, 2023 (2,208 shares); Performance Awards acquired on August 8, 2025 (6,346 shares); and Restricted Stock Awards acquired on February 29, 2024 (1,272 shares), August 31, 2021 (705 shares), February 28, 2020 (905 shares), and February 26, 2021 (706 shares). All securities were acquired from the issuer as compensation.
The filing also discloses 15 prior sales of Castle Biosciences common stock by Juvenal during the three months preceding the notice. Those transactions occurred on dates ranging from August 17, 2026 to October 28, 2026, with individual sale amounts ranging from 1,034 shares (gross proceeds of $35,362.59, on September 30, 2026) to 9,050 shares (gross proceeds of $317,112.09, on August 25, 2026). The filing states that all sales described, including the proposed sale, are made pursuant to a selling plan dated May 28, 2026, intended to comply with Rule 10b5-1(c) under the Exchange Act. The notice was signed by Goldman Sachs & Co. LLC on behalf of Tobin Juvenal.
What Was Disclosed
Castle Biosciences Chief Commercial Officer Tobin Juvenal filed a Form 144 on November 9, 2026, notifying of a proposed sale of 13,154 common shares valued at $452,234.52, executed through Goldman Sachs under a Rule 10b5-1 plan adopted May 28, 2026.




Please wait processing your request...